A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Camlipixant (Primary)
- Indications Cough
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CALM-2
- Sponsors BELLUS Health
Most Recent Events
- 09 Jun 2025 Planned number of patients changed from 825 to 975.
- 09 Jun 2025 Planned End Date changed from 1 Jun 2026 to 26 Apr 2027.
- 09 Jun 2025 Planned primary completion date changed from 1 Sep 2025 to 17 Jul 2026.